The Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1014-1017. doi: 10.1016/j.ijrobp.2018.01.063.
No abstract available

Publication types

  • Comment

MeSH terms

  • Androgen Antagonists*
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms*

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen